J
Joachim Schuhmacher
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 89
Citations - 453
Joachim Schuhmacher is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Hereditary angioedema & Carboxylic acid. The author has an hindex of 10, co-authored 89 publications receiving 440 citations. Previous affiliations of Joachim Schuhmacher include Bayer & Bayer Corporation.
Papers
More filters
Patent
Heterocyclic condensed pyridines as CETP inhibitors
Angerbauer Rolf,Bischoff Hilmar,Arndt Brandes,Bremm Klaus-Dieter,Loegers Michael,Mueller-Gliemann Matthias,Carsten Schmeck,Delf Schmidt,Gunther Schmidt,Joachim Schuhmacher +9 more
TL;DR: Condensed pyridine derivatives of formula (I), and their salts and N-oxides, are new as mentioned in this paper, where the rings are optionally substituted by NR9R10, NR3R4, NR5R6, NR6R7, NR8R9, NR10R10; NR11R11, NR12R12, NR13R13, NR14R14, NR15R15, NR16R16, NR17R17, NR18R18, NR19R19, NR20R20R21, NR21R
Journal ArticleDOI
Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
Anette Sommer,Charlotte Christine Kopitz,Christoph Schatz,Carl Friedrich Nising,Christoph Mahlert,Hans-Georg Lerchen,Beatrix Stelte-Ludwig,Stefanie Hammer,Simone Greven,Joachim Schuhmacher,Manuela Braun,Ruprecht Zierz,Sabine Wittemer-Rump,Axel Harrenga,Frank Dittmer,Frank Reetz,Heiner Apeler,Rolf Jautelat,Hung Huynh,Karl Ziegelbauer,Bertolt Kreft +20 more
TL;DR: Efficacy studies demonstrated that FGFR2-ADC treatment leads to a significant tumor growth inhibition or tumor regression of cell line-based or patient-derived xenograft models of human gastric or breast cancer.
Patent
4-(pyridin-3-yl)-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one derivatives as specific hif-prolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases
Flamme Ingo,Erguden Jens-Kerim,Felix Oehme,Kai Thede,Gunter Karig,Alexander Kuhl,Hanno Wild,Joachim Schuhmacher,Kolkhof Peter,Baerfacker Lars,Huetter Joachim +10 more
TL;DR: In this paper, the authors present an application related to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases, and their use in the preparation of medicaments for treatment or prevention of diseases.
Patent
Use of known agonists of the central cannabinoid receptor CB1
Joachim Mittendorf,Dressel Jurgen,Matzke Michael,Jürgen Franz,Peter Spreyer,Verena Voehringer,Joachim Schuhmacher,Arno Friedl,Ervin Horvath,Frank Mauler,Jean-Marie-Viktor De Vry,Reinhard Jork +11 more
TL;DR: In this paper, the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma, was described.
Patent
Substituted dihydropyrazolones for treating cardiovascular and hematological diseases
Kai Thede,Flamme Ingo,Felix Oehme,Erguden Jens-Kerim,Friederike Stoll,Joachim Schuhmacher,Wild Hanno,Kolkhof Peter,Beck Hartmut,Joerg Keldenich,Akbaba Metin,Jeske Mario +11 more
TL;DR: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use in the preparation of medicaments for treatment or prevention of diseases, in particular cardiovascular and hematological diseases and kidney diseases.